AI assistant
Syngene International Limited — Call Transcript 2026
Jan 17, 2026
61231_rns_2026-01-17_26012412-e480-476b-ada1-26db287e8ae2.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [113 x 28] intentionally omitted <==
Ref: Syn/CS/SE/Reg 30/2025-26/Jan/05
January 17, 2026
Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, 3, Bommasandra Industrial Area, IV JigPh a ni Link Road, Bengse, Jigani Link Ro a luru 560099, d, Bengaluru Karnataka, India. 560 099, Karnataka, India T +91 80 6891 9191 T +91 80 6891 8000 CIN: L85110KA1993PLC014937 F +91 80 6775 8808 CIN: L85110KA1993PLC www.syngeneintl.com 014937
| January 17, 2026 | www.syngeneintl.com |
|---|---|
| To,The Manager,BSE LimitedCorporate Relationship DepartmentDalal Street,Mumbai – 400 001 | To,The Manager,National Stock Exchange of India LimitedCorporate Communication DepartmentBandra(EAST),Mumbai – 400 051 |
| Scrip Code: 539268 | Scrip Symbol: SYNGENE |
Dear Sir/Madam,
Subject: Intimation of Conference Call for Analysts and Investors
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation for the conference call for Analysts and Investors to be held on Friday, January 23, 2026.
The above-mentioned information will also be available on the website of the Company www.syngeneintl.com.
Request to kindly take this intimation on record.
Thanking you,
Yours faithfully,
For SYNGENE INTERNATIONAL LIMITED
CHETHA Digitally signed by CHETHAN N YOGESH Date: 2026.01.17 YOGESH 15:54:10 +05'30' ______________ Chethan Yogesh
Company Secretary & Compliance Officer
INVESTOR CONFERENCE CALL INVITE
Q3 FY 2025-26
==> picture [594 x 151] intentionally omitted <==
Syngene’s Q3 and 9M FY2026 Results Conference Call
At 2:00 PM IST on 23[rd] January 2026
The management team of Syngene International Limited (“Syngene”) will organize a conference call for Analysts and Investors on Friday, 23[rd] January 2026 at 2:00 pm IST following the announcement of financial results for the quarter ended December 2025.
The call will be initiated with a brief management discussion on the Q3 & 9M FY2026 performance followed by an interactive Question & Answer session. Mr. Peter Bains - Syngene’s Managing Director and Chief Executive Officer - and other members of the senior management team will represent Syngene on the conference call.
Details of the conference call are as under:
| Date: | Friday, 23rdJanuary 2026 |
|---|---|
| Time: | 2:00 pm to 3:00 pm IST |
| Dial-in Numbers* | |
| Primary Number | +91 22 6280 1279/ 91 22 7115 8180 |
| International Numbers | USA – 18667462133UK – 08081011573Singapore – 8001012045Hong Kong – 800964448Australia – 0080014243444 |
| Pre-registration Facility(Diamond_Pass_™link) | Step 1: Pre-register here .You will receive a passcode and a pin for thecall on the registered email address.Step 2: Dial into the call on the Conference Call date, enter the passcode& pin as prompted. You will be directly connected to the call. |
*When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time
Syngene International: Putting Science to Work
Page 1
==> picture [594 x 151] intentionally omitted <==
INVESTOR CONFERENCE CALL INVITE
Q3 FY 2025-26
Participants can also join the webcast with https://links.ccwebcast.com/?EventId=SYG230126 the link:
Replay/Audio Facility Dial in numbers: +91 22 71945757 Playback ID: 73641 The replay facility will be available from 23[rd] January 2026 till 30[th] January 2026 The audio facility will also be available on the corporate website: https://syngeneintl.com/ Conference Call Transcript Will be available within 7 working days of the call on the corporate website.
About Syngene
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s team of over 8,200 employees including 5,600 scientists, brings both deep expertise and the capacity to deliver scientific excellence, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With over 2.5 mn sq. ft of specialized discovery, development, and manufacturing facilities across India and the U.S., Syngene works with 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company’s latest Environmental, Social, and Governance (ESG) report, visit Syngene ESG Report.
For further information, please contact:
Nandini Agarwal / Shubham Jain P: +91 80 6891 9807 M: +91 7838382527 / 6377651994 E: [email protected] E: [email protected]
Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene, and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.
Syngene International: Putting Science to Work
Page 2